好酸球性食道炎患者におけるベンラリズマブの研究

基本情報

NCT ID

NCT04543409

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

211

治験依頼者名

AstraZeneca

概要

The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity. Upon completion of the initial 52-week treatment period, patients will be offered an additional Open Label Extension period of at least 1 year, with benralizumab treatment and ongoing study assessments.

対象疾患

介入

依頼者（Sponsor）